---
title: "Nidan Laboratories & Healthcare Ltd (NIDAN) — Share Price, Financials & Analysis"
symbol: "NIDAN"
company: "Nidan Laboratories & Healthcare Ltd"
canonical: "https://tapetide.com/stocks/NIDAN"
isin: "INE0J6L01013"
nse_symbol: "NIDAN"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 18.28
generated_at: "2026-09-13T18:34:53.160Z"
---

# Nidan Laboratories & Healthcare Ltd (NIDAN)

Canonical page: https://tapetide.com/stocks/NIDAN

## Company

- **NSE Symbol:** NIDAN
- **ISIN:** INE0J6L01013
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2021-11-12
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** nidanhealthcare.co.in

## About

Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]

## Latest Price

- **Price:** ₹13.5
- **Change:** +0.35 (+2.66%)
- **Open:** ₹12.9
- **Day High:** ₹13.8
- **Day Low:** ₹12.9
- **Previous Close:** ₹13.15
- **Volume:** 4000
- **As Of:** 2026-09-11T07:43:25+00:00

## Key Fundamentals

Observed at 2026-09-11T04:38:12.209582Z.

- **Market Cap:** ₹18.28 Cr
- **Classification:** SME
- **P/E (reported):** 12.2
- **EPS (reported):** ₹1.5
- **Book Value:** ₹50.14
- **Price to Book:** 0.26
- **Dividend Yield:** 0%
- **ROE:** 2.9%
- **ROCE:** 6.74%
- **Debt to Equity:** 0.16
- **Revenue (yearly):** ₹25.54 Cr
- **Net Income:** ₹1.64 Cr
- **EBITDA:** ₹4.44 Cr
- **52-Week High:** ₹24.9
- **52-Week Low:** ₹11.5
- **RSI (14):** 46.95

## Tapetide Score

- **Score:** 57 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Falling
- **Percentile:** 77.8 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 47.74 | 9% |
| growth | 42.62 | 9% |
| momentum | 32.77 | 12% |
| ownership | 50 | 24% |
| quality | 60.03 | 22% |
| valuation | 80.34 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.27 times its book value
- Company's working capital requirements have reduced from 87.8 days to 33.6 days

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.62% over past five years.
- Company has a low return on equity of 1.81% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.2%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -58.7% | -79.22% | -47.59% |
| ebitda margin growth | 81.25% | -40.68% | -52.55% | -50.38% |
| net income growth | 63.64% | -18% | -19% | -5% |
| revenue growth | 111.54% | -4.7% | 2% | 5% |
| roce | — | — | -28.3% | 9.98% |
| roe | — | -159.43% | 1.04% | -83.21% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 13.14 | 14.09 | 10.18 | 11.82 | 12.35 | 10.53 | 13.99 | 13.12 | 12.42 |
| Expenses | 9.52 | 8.93 | 8.54 | 8.48 | 9.24 | 7.93 | 11.53 | 10.58 | 10.12 |
| Operating Profit | 3.62 | 5.16 | 1.64 | 3.34 | 3.11 | 2.6 | 2.46 | 2.54 | 2.3 |
| OPM % | 27.55 | 36.62 | 16.11 | 28.26 | 25.18 | 24.69 | 17.58 | 19.36 | 18.52 |
| Other Income | 0.39 | 0.33 | 3 | 1.52 | -5.29 | 1.03 | 1.22 | 1.17 | 0.29 |
| Interest | 0.95 | 1.03 | 1.19 | 0.98 | 1.2 | 0.88 | 1.26 | 0.88 | 1.07 |
| Depreciation | 0.87 | 1.44 | 1.66 | 1.28 | 1.59 | 1.34 | 1.07 | 0.92 | 0.98 |
| Profit before tax | 2.19 | 3.02 | 1.79 | 2.6 | -4.97 | 1.41 | 1.35 | 1.91 | 0.54 |
| Tax % | 61.19 | 23.51 | 31.28 | 26.15 | 3.62 | 21.99 | 34.81 | 24.61 | 87.04 |
| Net Profit | 0.86 | 2.32 | 1.22 | 1.92 | -5.15 | 1.1 | 0.88 | 1.43 | 0.07 |
| EPS in Rs | 0.62 | 1.67 | 0.88 | 1.38 | -3.71 | 0.79 | 0.63 | 1.03 | 0.05 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 25.54 |
| Expenses | 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 20.7 |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.8 | 6.44 | 5.06 | 4.84 |
| OPM % | 39.06 | 35.64 | 43.62 | 31.73 | 28.02 | 26.63 | 20.63 | 18.95 |
| Other Income | 0.37 | 0.01 | 1.06 | 0.4 | 3.33 | -3.76 | 2.25 | 1.46 |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 1.96 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.1 | 2.87 | 2.41 | 1.9 |
| Profit before tax | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | -2.37 | 2.76 | 2.44 |
| Tax % | 0 | 0 | 30.21 | 41.15 | 26.4 | 36.29 | 28.26 | 38.11 |
| Net Profit | 0.22 | 0.71 | 2.3 | 2.66 | 3.54 | -3.23 | 1.98 | 1.51 |
| EPS in Rs | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | -2.32 | 1.42 | 1.09 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 9.9 | 9.9 | 9.9 | 13.9 | 13.9 | 13.9 | 13.9 | 13.9 |
| Reserves | 0.41 | 1.13 | 3.43 | 52 | 55.54 | 52.31 | 54.28 | 55.79 |
| Borrowings | 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 11.17 |
| Other Liabilities | 0.58 | -0.17 | 2.37 | 3.29 | 4.03 | 3.9 | 3.65 | 3.14 |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.4 | 82.55 | 82.94 | 84 |
| Fixed Assets | 23.28 | 20.1 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 14.91 |
| CWIP | 0 | 0 | 0.23 | 3.81 | 0 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0 | 0 | 0 | 20 | 20 |
| Other Assets | 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 48.94 |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.4 | 82.55 | 82.94 | 84 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.28 | 1.67 |
| Cash from Investing Activity | 1 | -0.01 | -3.22 | -35.74 | -0.29 | -10.6 | -0.22 | 0.06 |
| Cash from Financing Activity | -5.81 | -1.56 | -1.22 | 28.72 | -10.37 | -0.49 | -3.01 | -1.63 |
| Net Cash Flow | 4.14 | 3.05 | -0.1 | 0.8 | 0.32 | -5.57 | -0.95 | 0.1 |
| Free Cash Flow | 9.95 | 4.61 | 1.13 | 1.36 | 11.02 | 4.88 | 1.41 | 1.19 |
| CFO/OP | 114 | 61 | 49 | 96 | 162 | 129 | 77 | 55 |

### Ratios

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 102.03 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.9 | 31.73 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | — | — | — | — |
| Days Payable | 116.72 | -25.76 | 213.05 | 135.84 | — | — | — | — |
| Cash Conversion Cycle | 2.29 | 131.22 | -97.64 | -43.89 | 90.69 | 7.85 | 18.9 | 31.73 |
| Working Capital Days | 256.25 | 291.69 | -189.31 | 54.52 | 43.46 | 243.18 | -13.39 | 33.58 |
| ROCE % | — | 10.13 | 13.99 | 10.09 | 8.17 | 7.95 | 6.17 | 5.99 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 71.22% | 71.22% | 71.22% | 62.79% | 57.04% | 57.04% | 57.04% | 57.04% | 57.04% | 57.04% | 57.04% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 26.6% | 25.63% | 26.62% | 33.22% | 39.33% | 39.6% | 39.78% | 40.01% | 40.05% | 40.05% | 39.94% |
| Others | 2.18% | 3.15% | 2.16% | 3.99% | 3.64% | 3.36% | 3.18% | 2.95% | 2.92% | 2.92% | 3.02% |
| No. of Shareholders | 2791 | 2516 | 2440 | 2777 | 2864 | 2790 | 2581 | 2489 | 2437 | 2362 | 2359 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 13.68 | Sell |
| EMA (10) | 13.67 | Sell |
| SMA (20) | 13.66 | Sell |
| EMA (20) | 13.64 | Sell |
| SMA (50) | 13.5 | Sell |
| EMA (50) | 13.68 | Sell |
| SMA (100) | 13.94 | Sell |
| EMA (100) | 14.22 | Sell |
| SMA (200) | 15.91 | Sell |
| EMA (200) | 15.59 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 49.21 | Neutral |
| MACD (12,26,9) | 0.04 | Sell |
| Stochastic (14,3,3) | 28.36 | Neutral |
| ADX (14) | 23.12 | Neutral |
| Williams %R (14) | -71.64 | Neutral |
| ATR (14) | 0.99 | High Volatility |
| ROC (12) | 1.5 | Buy |
| Stoch RSI (14) | 34.03 | Neutral |
| UO (7,14,28) | 50.21 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jul - Corporate governance regulations not applicable for quarter ended 30 June 2026 under SME exemption. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 9 Jul - Corporate governance regulations not applicable for quarter ended 30 June 2026 under SME exemption.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_09072026121734_Nidan_Non_applicability_CG_30062026.pdf) |
| 8 April 2026 - Submitted Regulation 74(5) demat certificate for quarter ended 31 March 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 April 2026 - Submitted Regulation 74(5) demat certificate for quarter ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_08042026135257_Nidan_74_Letter_Signed--.pdf) |
| 7 March 2026 - Postal ballot (6 Feb–7 Mar 2026): five related-party resolutions approved; ~99.45% favor, 1.32% turnout. | [Shareholders meeting 7 March 2026 - Postal ballot (6 Feb–7 Mar 2026): five related-party resolutions approved; ~99.45% favor, 1.32% turnout.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_07032026182740_Scrutinizers_Report-Reg_44-Postal_Ballot_2026S_dsc_affixed.pdf) |
| 6 February 2026 - Postal Ballot Notice published; remote e-voting 06 Feb–07 Mar 2026; results by 09 Mar 2026. | [Copy of Newspaper Publication 6 February 2026 - Postal Ballot Notice published; remote e-voting 06 Feb–07 Mar 2026; results by 09 Mar 2026.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_06022026132646_Intimation-PublicationofPBNotice-Nidan-05022026_signed.pdf) |
| 5 February 2026 - Postal ballot to approve RPTs: Rs50Cr with Junnar Sugars; Rs5Cr each with four parties. E-voting Feb6–Mar7. | [Shareholders meeting 5 February 2026 - Postal ballot to approve RPTs: Rs50Cr with Junnar Sugars; Rs5Cr each with four parties. E-voting Feb6–Mar7.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_05022026131910_Nidan-Intimation_of_Postal_Ballot_Notice_-05-02-2026-----.pdf) |
| 5 February 2026 - Board approved postal ballot for related party transactions; appointed Pusalkar & Co. as scrutinizer; e-voting via CDSL. | [Outcome of Board Meeting 5 February 2026 - Board approved postal ballot for related party transactions; appointed Pusalkar & Co. as scrutinizer; e-voting via CDSL.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_05022026131409_Nidan-Outcome-05-02-2026--.pdf) |
| 3 Sep - 26th AGM on 28 September 2026; book closure 22-28 September, remote e-voting enabled. | [Copy of Newspaper Publication 3 Sep - 26th AGM on 28 September 2026; book closure 22-28 September, remote e-voting enabled.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_03092026134020_Nidan-NSE_Letter-Newspaper_ad.pdf) |
| 3 April 2026 - Nidan Laboratories says Regulation 24A annual secretarial compliance report is not applicable. | [Updates 3 April 2026 - Nidan Laboratories says Regulation 24A annual secretarial compliance report is not applicable.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_03042026165737_Nidan_Non_Applicablility_-_24A_2026_Pdf.pdf) |
| 29 April 2026 - SEBI issued SCN over alleged misuse of Rs.29.99 crore IPO proceeds and misstatements in FY22-FY23. | [Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company 29 April 2026 - SEBI issued SCN over alleged misuse of Rs.29.99 crore IPO proceeds and misstatements in FY22-FY23.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_29042026164818_Intimation_to_NSE_for_Showcause_Notice_SEBI.pdf) |
| 28 April 2026 - Filed SDD compliance certificate for FY ended 31 March 2026. | [Structural Digital Database 28 April 2026 - Filed SDD compliance certificate for FY ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/NIDANHEALTHCARE_28042026162442_SDD_Nidan-31032026_allsigned.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31076_NIDAN_2025_2026_A_1832434_02092026130729.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27355_NIDAN_2024_2025_A_08082025153357.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25554_NIDAN_2023_2024_03092024162054.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_23174_NIDAN_2022_2023_01092023123801_09012023130003.zip) |
| from nse | [Annual Report 2022 from nse](https://archives.nseindia.com/annual_reports/SME_AR_21075_NIDAN_2021_2022_02092022145915_09022022150007.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:34:53.160Z.